1. Home
  2. TSLX vs NRIX Comparison

TSLX vs NRIX Comparison

Compare TSLX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$18.21

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.13

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
NRIX
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
TSLX
NRIX
Price
$18.21
$16.13
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$21.72
$30.58
AVG Volume (30 Days)
899.7K
1.1M
Earning Date
05-05-2026
04-10-2026
Dividend Yield
11.05%
N/A
EPS Growth
N/A
N/A
EPS
1.81
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.92
$26.32
P/E Ratio
$10.25
N/A
Revenue Growth
N/A
99.31
52 Week Low
$16.99
$8.18
52 Week High
$25.17
$22.50

Technical Indicators

Market Signals
Indicator
TSLX
NRIX
Relative Strength Index (RSI) 48.07 55.45
Support Level $17.25 $14.61
Resistance Level $18.57 $16.47
Average True Range (ATR) 0.49 0.92
MACD 0.13 0.16
Stochastic Oscillator 58.14 68.29

Price Performance

Historical Comparison
TSLX
NRIX

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: